Epidiolex cannabidiol: Phase III started

GW began a double-blind, placebo-controlled, international Phase III trial to evaluate 25 and 50 mg/kg/day oral Epidiolex for 16 weeks as add-on therapy in about 200 patients ages 1-65 with seizures a...